ADAP

0.595

1.43% 0.0084

Dopo l'orario di chiusura: .64 0.045 +7.56%

Adaptimmune Therapeutics Plc Adr (ADAP)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$0.5866

Aprire:

$0.6

Volume 24 ore:

1.79M

Relative Volume:

1.30

Capitalizzazione di mercato:

$158.36M

Reddito:

$175.04M

Utile/perdita netta:

$-44.52M

Rapporto P/E:

-1.1146

EPS:

-0.5338

Flusso di cassa netto:

$-56.05M

1 W Prestazione:

-27.80%

1M Prestazione:

-29.39%

6M Prestazione:

-46.40%

1 anno Prestazione:

+24.22%

Intervallo 1D:

$0.58

$0.6393

Intervallo di 1 settimana:

$0.58

$0.8334

Portata 52W:

$0.42

$2.05

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Nome

Adaptimmune Therapeutics Plc Adr

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

44 1235 430000

Indirizzo

60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE

Dipendente

449

Cinguettio

@Adaptimmune

Prossima data di guadagno

2024-12-13

Ultimi documenti SEC

ADAP's Discussions on Twitter

Confronta ADAP con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ADAP	0.595	158.36M	175.04M	-44.52M	-56.05M	-0.5338
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-03-24	Iniziato	Bryan Garnier	Buy
2023-01-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-11-09	Aggiornamento	Mizuho	Neutral → Buy
2021-05-28	Iniziato	Barclays	Underweight
2020-04-22	Iniziato	Mizuho	Neutral
2019-08-02	Downgrade	Guggenheim	Buy → Neutral
2019-05-31	Iniziato	ROTH Capital	Buy
2019-05-30	Ripresa	Citigroup	Buy
2019-05-07	Downgrade	SVB Leerink	Outperform → Mkt Perform
2017-03-17	Iniziato	Wells Fargo	Market Perform
2016-10-24	Downgrade	BofA/Merrill	Neutral → Underperform
2016-09-30	Iniziato	Raymond James	Outperform
2016-02-25	Iniziato	Citigroup	Buy
2015-06-01	Iniziato	BofA/Merrill	Neutral
2015-06-01	Iniziato	Guggenheim	Buy
2015-06-01	Iniziato	Leerink Partners	Outperform

Mostra tutto

Adaptimmune Therapeutics Plc Adr Borsa (ADAP) Ultime notizie

08:32 AM

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

08:32 AM

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

08:32 AM

Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024

Nov 01, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024

Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024

Oct 10, 2024

Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily

Oct 10, 2024

Oct 09, 2024

The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle

Oct 09, 2024

Oct 08, 2024

Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News

Oct 08, 2024

Oct 07, 2024